Routine data underestimates the incidence of first-line antiretroviral drug discontinuations due to adverse drug reactions: Observational study in two South African cohorts
Open Access
- 5 September 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (9) , e0203530
Abstract
Estimating the incidence of antiretroviral discontinuations due to adverse drug reactions (ADRs) is important to inform antiretroviral treatment (ART) regimen recommendations, and to guide prescribing and monitoring policies. Routinely collected clinical data is a useful source of pharmacovigilance data. We estimated the incidences of first-line antiretroviral discontinuations due to ADRs using routine clinical data, and compared them with incidences estimated using data enhanced by folder review, in two South African cohorts. We included patients 16 years and older on first-line ART. We selected a stratified random sample of 25% for checking of ART prescription data and reasons for antiretroviral discontinuations retrospectively, including folders reviews where required (enhanced-data sample). We estimated the incidence of antiretroviral discontinuations using Kaplan-Meier and competing risk analyses. In 15396 patients, 40% had a first-line antiretroviral discontinuation by three years on ART. We could determine the reason for 65% of discontinuations using routine data only, and 84% of discontinuations, in the enhanced-data sample of 3837 patients. ADR was the most common reason for discontinuations. In the enhanced-data sample, the cumulative incidence of discontinuations due to ADRs by three years was 30.4% (95% CI: 24.4–36.6) for stavudine; 2.0% (95% CI: 1.5–2.6) for tenofovir, and 1.3% (95% CI: 0.8–2.1) for efavirenz. Using routine data only, the cumulative incidences of discontinuations due to ADRs by three years for stavudine, tenofovir, and efavirenz respectively were 23.9% (95% CI: 20.3–27.7), 1.2% (95% CI: 0.9–1.4) and 0.5% (95% CI: 0.3–0.7). Although the relative rankings were similar using routine or enhanced data, lack of checking for missing reasons for discontinuation resulted in underestimates of the incidence of antiretroviral discontinuations due to ADRs. Systems to improve data collection of reasons for regimen changes prospectively would increase the capacity of routine data to answer pharmacovigilance questions.Keywords
Funding Information
- Centers for Disease Control and Prevention (GH000371)
This publication has 18 references indexed in Scilit:
- Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort StudyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2018
- Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa?AIDS, 2017
- Pharmacovigilance and global HIV/AIDSCurrent Opinion in HIV and AIDS, 2012
- Cohort Profile: The Themba Lethu Clinical Cohort, Johannesburg, South AfricaInternational Journal of Epidemiology, 2012
- Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South AfricaAIDS, 2010
- Sustainability of First-Line Antiretroviral Regimens: Findings From a Large HIV Treatment Program in Western KenyaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Treatment Modification in Human Immunodeficiency Virus–Infected Individuals Starting Combination Antiretroviral Therapy Between 2005 and 2008Archives of internal medicine (1960), 2010
- Faculty Opinions recommendation of Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort.2007
- Improvement of the study, analysis, and reporting of adverse events associated with antiretroviral therapyThe Lancet, 2002
- Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centreAIDS, 2001